Kindred Biosciences, Inc. (KIN) SEC Filing 8-K Material Event for the period ending Friday, October 19, 2018

Kindred Biosciences, Inc.

CIK: 1561743 Ticker: KIN

View differences made from one to another to evaluate Kindred Biosciences, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Kindred Biosciences, Inc..


Assess how Kindred Biosciences, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Kindred Biosciences, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools

Material Contracts, Statements, Certifications & more

Kindred Biosciences, Inc. provided additional information to their SEC Filing as exhibits

Ticker: KIN
CIK: 1561743
Form Type: 8-K Corporate News
Accession Number: 0001561743-18-000084
Submitted to the SEC: Thu Oct 25 2018 4:31:14 PM EST
Accepted by the SEC: Thu Oct 25 2018
Period: Friday, October 19, 2018
Industry: Pharmaceutical Preparations
  1. Event for Officers
  2. Other Events

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: